{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:50:31Z","timestamp":1789822231484,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA037012"],"award-info":[{"award-number":["R01 DA037012"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K24 DA039780"],"award-info":[{"award-number":["K24 DA039780"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA046697"],"award-info":[{"award-number":["K01DA046697"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Numerous reports have led to concerns that fentanyl is added to many street drugs as an adulterant, including to stimulants like cocaine and methamphetamine, and could increase risks for negative health outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected information regarding recent substance use through self-report and urine toxicology (confirmed with mass spectrometry) once a month for up to 6 monthly study visits from a probability sample of 245 women in San Francisco with a history of housing instability (2016-2019). We compared the presence of fentanyl metabolites with (1) the presence of metabolites for other substances and (2) self-reported past week substance use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 1050 study visits, fentanyl metabolites were detected 35 times (i.e., at 3% of all study visits and among 19\/245, or 8% of all women). In most but not all (91%, or 32\/35) of these detected cases, heroin or opioid medication use was self-reported. Among women who reported cocaine or methamphetamine use, but did not use heroin or opioid medication, fentanyl was detected in only 1 of 349 cases (0.3%). In adjusted logistic regression, the presence of fentanyl metabolites was independently associated with (1) presence of opiate, heroin, and benzodiazepine metabolites, and (2) self-reported past week use of heroin and opioid medications. Fentanyl metabolite detection was not independently associated with cocaine or methamphetamine use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presence of fentanyl metabolites in this population was almost entirely among women who also reported using heroin or opioid pills. These data do not support the hypothesis that fentanyl is being routinely added to stimulants as an adulterant on a large scale in this region.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-020-00361-8","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T11:02:50Z","timestamp":1583838170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Addressing overdose risk among unstably housed women in San Francisco, California: an examination of potential fentanyl contamination of multiple substances"],"prefix":"10.1186","volume":"17","author":[{"given":"Meredith C.","family":"Meacham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip O.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise D.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"issue":"17","key":"361_CR1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","volume":"319","author":"CM Jones","year":"2018","unstructured":"Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. Jama. 2018;319(17):1819\u201321.","journal-title":"Jama."},{"issue":"5152","key":"361_CR2","first-page":"1419","volume":"67","author":"L Scholl","year":"2019","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morbidity and mortality weekly report. 2019;67(5152):1419\u201327.","journal-title":"MMWR Morbidity and mortality weekly report."},{"issue":"1","key":"361_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11524-018-00343-z","volume":"96","author":"ML Nolan","year":"2019","unstructured":"Nolan ML, Shamasunder S, Colon-Berezin C, Kunins HV, Paone D. Increased presence of fentanyl in cocaine-involved fatal overdoses: implications for prevention. Journal of urban health : bulletin of the New York Academy of Medicine. 2019;96(1):49\u201354.","journal-title":"Journal of urban health : bulletin of the New York Academy of Medicine."},{"key":"361_CR4","unstructured":"Sawyer N. Fentanyl rising in S.F.\u2019s street drug supply. SF Weekly. 2018."},{"key":"361_CR5","unstructured":"Harm Reduction Coalition. Worlds away in a 7x7: perspectives on reaching diverse groups of people who use drugs to prevent fentanyl-related overdose in San Francisco. Oakland, California: 2018."},{"key":"361_CR6","unstructured":"San Francisco Department of Public Health. Health advisory: possible fentanyl overdose deaths due to stimulant use in San Francisco. San Francisco, California: 2018. Available from: https:\/\/www.sfcdcp.org\/wp-content\/uploads\/2018\/02\/FentanylAdvisory_02.2018.pdf. Accessed 4 Mar 2020."},{"key":"361_CR7","unstructured":"San Francisco Department of Public Health. Health advisory: opioid overdoses in San Francisco due to fentanyl-containing \u201cCrack\u201d Cocaine. San Francisco, CA: 2017. Available from: https:\/\/www.sfcdcp.org\/wp-content\/uploads\/2018\/01\/Overdose_publichealthadvisory_05082017-id1176.pdf. Accessed 4 Mar 2020."},{"key":"361_CR8","unstructured":"San Francisco Department of Public Health. Health advisory: severe opioid overdoses in San Francisco caused by fentanyl-containing \u201cXanax\u201d pill. San Francisco, CA: 2017. Available from: https:\/\/www.sfcdcp.org\/wp-content\/uploads\/2017\/12\/Overdose_publichealthadvisory_102215_final.pdf. Accessed 4 Mar 2020."},{"key":"361_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. The International journal on drug policy. 2017;46:107\u201311.","journal-title":"The International journal on drug policy."},{"issue":"1","key":"361_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/00952990.2018.1550652","volume":"45","author":"JJ Palamar","year":"2019","unstructured":"Palamar JJ, Salomone A, Bigiarini R, Vincenti M, Acosta P, Tofighi B. Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. The American journal of drug and alcohol abuse. 2019;45(1):90\u20136.","journal-title":"The American journal of drug and alcohol abuse."},{"issue":"3","key":"361_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamapsychiatry.2017.4432","volume":"75","author":"AA Jones","year":"2018","unstructured":"Jones AA, Jang K, Panenka WJ, Barr AM, MacEwan GW, Thornton AE, et al. Rapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA psychiatry. 2018;75(3):298\u2013300.","journal-title":"JAMA psychiatry."},{"key":"361_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2018.01.005","volume":"86","author":"SR Kenney","year":"2018","unstructured":"Kenney SR, Anderson BJ, Conti MT, Bailey GL, Stein MD. Expected and actual fentanyl exposure among persons seeking opioid withdrawal management. J Subst Abuse Treat. 2018;86:65\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"361_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","volume":"12","author":"A Amlani","year":"2015","unstructured":"Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm reduct j. 2015;12:54.","journal-title":"Harm reduct j"},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.020","volume":"190","author":"KW Tupper","year":"2018","unstructured":"Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug and alcohol dependence. 2018;190:242\u20135.","journal-title":"Drug and alcohol dependence."},{"issue":"3","key":"361_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.drugpo.2013.10.011","volume":"25","author":"KR Knight","year":"2014","unstructured":"Knight KR, Lopez AM, Comfort M, Shumway M, Cohen J, Riley ED. Single room occupancy (SRO) hotels as mental health risk environments among impoverished women: the intersection of policy, drug use, trauma, and urban space. Int J Drug Policy. 2014;25(3):556\u201361.","journal-title":"Int J Drug Policy."},{"issue":"12","key":"361_CR16","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/add.14417","volume":"113","author":"J Boyd","year":"2018","unstructured":"Boyd J, Collins AB, Mayer S, Maher L, Kerr T, McNeil R. Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Addiction. 2018;113(12):2261\u201370.","journal-title":"Addiction"},{"issue":"4","key":"361_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.socscimed.2007.11.008","volume":"66","author":"K Shannon","year":"2008","unstructured":"Shannon K, Kerr T, Allinott S, Chettiar J, Shoveller J, Tyndall MW. Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med. 2008;66(4):911\u201321.","journal-title":"Soc Sci Med"},{"issue":"2","key":"361_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/dta.220","volume":"3","author":"C Cole","year":"2011","unstructured":"Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Testing and Analysis. 2011;3(2):89\u201396.","journal-title":"Drug Testing and Analysis."},{"issue":"4","key":"361_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/16066359709004344","volume":"5","author":"R Coomber","year":"1997","unstructured":"Coomber R. The adulteration of drugs: what dealers do to illicit drugs, and what they think is done to them. Addiction Res. 1997;5(4):297\u2013306.","journal-title":"Addiction Res"},{"key":"361_CR20","volume-title":"Pusher myths: re-situating the drug dealer","author":"R Coomber","year":"2006","unstructured":"Coomber R. Pusher myths: re-situating the drug dealer; 2006."},{"key":"361_CR21","unstructured":"Zibbell JE. The latest evolution of the opioid crisis: changing patterns in fentanyl adulteration of heroin, cocaine, and methamphetamine and associated overdose risk. RTI International, 2019. Available from: https:\/\/www.rti.org\/insights\/latest-evolution-opioid-crisis-changing-patterns-fentanyl-adulteration-heroin-cocaine-and. Accessed 4 Mar 2020."},{"key":"361_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"361_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11524-018-0250-x","volume":"96","author":"C Rowe","year":"2019","unstructured":"Rowe C, Wheeler E, Stephen Jones T, Yeh C, Coffin PO. Community-based response to fentanyl overdose outbreak, San Francisco, 2015. J Urban Health. 2019;96(1):6\u201311.","journal-title":"J Urban Health"},{"key":"361_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"361_CR25","unstructured":"Harm Reduction Coalition. Fentanyl. 2019. Available from: https:\/\/harmreduction.org\/issues\/fentanyl\/. Accessed 4 Mar 2020."},{"key":"361_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugpo.2018.10.001","volume":"62","author":"MK Laing","year":"2018","unstructured":"Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59\u201366.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"361_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1176\/appi.ps.201700235","volume":"69","author":"CL Barry","year":"2018","unstructured":"Barry CL. Fentanyl and the evolving opioid epidemic: what strategies should policy makers consider. Psychiatr Serv. 2018;69(1):100\u20133.","journal-title":"Psychiatr Serv"},{"issue":"9775","key":"361_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","volume":"377","author":"BD Marshall","year":"2011","unstructured":"Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429\u201337.","journal-title":"Lancet"},{"key":"361_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugpo.2018.08.004","volume":"60","author":"C McKnight","year":"2018","unstructured":"McKnight C, Des Jarlais DC. Being \u201chooked up\u201d during a sharp increase in the availability of illicitly manufactured fentanyl: adaptations of drug using practices among people who use drugs (PWUD) in New York City. Int J Drug Policy. 2018;60:82\u20138.","journal-title":"Int J Drug Policy"},{"key":"361_CR30","unstructured":"Mars SG, Rosenblum D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2018;114(5):774\u201380."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-020-00361-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:17:52Z","timestamp":1615335472000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00361-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study procedures were approved by the Institutional Review Board of the University of California, San Francisco. All participants completed informed consent procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}